Table 3.
Baseline characteristics.
| Characteristic | Head and Neck (n = 119) n (%) |
Esophageal (n = 51) n (%) |
All (n = 170) n (%) |
|---|---|---|---|
| Centre (Country–City) | |||
| Australia–Brisbane | 10 (8.4%) | 0 (0.0%) | 10 (5.9%) |
| Australia–Sydney | 20 (16.8%) | 0 (0.0%) | 20 (11.8%) |
| Canada-Calgary * | 21 (17.6%) | 10 (19.6%) | 31 (18.2%) |
| Canada–Edmonton * | 20 (16.8%) | 18 (35.3%) | 38 (22.4%) |
| Italy–Rome | 19 (16.0%) | 0 (0.0%) | 19 (11.2%) |
| Netherlands-Amsterdam | 20 (16.8%) | 23 (45.1%) | 43 (25.3%) |
| USA-Sacramento | 9 (7.6%) | 0 (0.0%) | 9 (5.3%) |
| Age, years | |||
| median [Q1, Q3] | 62 [58, 69] | 65 [56, 71] | 63 [57, 70] |
| Sex | |||
| Male | 93 (78.2%) | 41 (80.4%) | 134 (78.8%) |
| Female | 26 (21.8%) | 10 (19.6%) | 36 (21.2%) |
| Ethnicity | |||
| Caucasian | 111 (93.3%) | 50 (98.0%) | 161 (94.7%) |
| First Nations | 1 (0.8%) | 0 (0.0%) | 1 (0.6%) |
| Hispanic | 2 (1.7%) | 0 (0.0%) | 2 (1.2%) |
| Asian | 3 (2.5%) | 1 (2.0%) | 4 (2.4%) |
| East Indian | 1 (0.8%) | 0 (0.0%) | 1 (0.6%) |
| Other | 1 (0.8%) | 0 (0.0%) | 1 (0.6%) |
| Current Smoker | |||
| Yes | 44 (37.0%) | 13 (25.5%) | 57 (33.5%) |
| No | 75 (63.0%) | 38 (74.5%) | 113 (66.5%) |
| Alcohol use | |||
| Yes | 47 (39.5%) | 9 (17.6%) | 56 (32.9%) |
| No | 72 (60.5%) | 42 (82.4%) | 114 (67.1%) |
| ECOG a Performance Status | |||
| 0 | 78 (65.5%) | 32 (62.7%) | 110 (64.7%) |
| 1 | 32 (26.9%) | 16 (31.4%) | 48 (28.2%) |
| 2 | 6 (5.0%) | 3 (5.9%) | 9 (5.3%) |
| 3 | 3 (2.5%) | 0 (0.0%) | 3 (1.8%) |
| Clinical Stage | |||
| 1 | 5 (4.2%) | 4 (7.8%) | 9 (5.3%) |
| 2 | 8 (6.7%) | 13 (25.5%) | 21 (12.4%) |
| 3 | 18 (15.1%) | 15 (29.4%) | 33 (19.4%) |
| 4 (Any) | 74 (62.2%) | 4 (7.8%) | 78 (45.9%) |
| Could not assess stage | 7 (5.9%) | 11 (21.6%) | 16 (10.6%) |
| Not staged | 7 (5.9%) | 4 (7.8%) | 11 (6.5%) |
| Tumor Site–Head and Neck | |||
| Primary unknown | 3 (2.5%) | 3 (1.8%) | |
| Hypopharynx | 10 (8.4%) | 10 (5.9%) | |
| Larynx | 22 (18.5%) | 22 (12.9%) | |
| Nasopharynx | 5 (4.2%) | 5 (2.9%) | |
| Oral cavity | 32 (26.9%) | 32 (18.8%) | |
| Oropharynx | 39 (32.8%) | 39 (22.9%) | |
| Other | 3(2.5%) | 3 (1.8%) | |
| Salivary gland | 5 (4.2%) | 5 (2.9%) | |
| Treatment Modality b | |||
| None | 5 (5.0%) | 5 (9.8%) | 10 (6.6%) |
| Chemotherapy-definitive | 0 (0.0%) | 2 (3.9%) | 2 (1.3%) |
| Chemotherapy-adjuvant | 0 (0.0%) | 1 (2.0%) | 1(0.7%) |
| Radiotherapy-definitive | 15 (15.0%) | 0 (0.0%) | 15 (9.9%) |
| Surgery | 10 (10.0%) | 2 (3.9%) | 12 (7.9%) |
| Chemoradiotherapy-definitive | 54 (54.0%) | 6 (11.8%) | 60 (39.7%) |
| Surgery + adj c/neoadj d RT e | 7 (7.0%) | 0 (0.0%) | 7 (4.6%) |
| Surgery + adj/neoadj CRT f | 9 (9.0%) | 35 (68.6%) | 44 (29.1%) |
* 3 participating sites each from Edmonton and Calgary. a ECOG = European Co-Operative Group; b Treatment modality–19 patients from one site (Rome, Italy) excluded because cancer treatment was not captured; c adj = adjuvant; d neoadj = neoadjuvant; e RT = Radiotherapy; f CRT = Chemoradiotherapy.